AU2021104419A4 - Polyherbal Gel formulation for growth of Hair Follicle - Google Patents
Polyherbal Gel formulation for growth of Hair Follicle Download PDFInfo
- Publication number
- AU2021104419A4 AU2021104419A4 AU2021104419A AU2021104419A AU2021104419A4 AU 2021104419 A4 AU2021104419 A4 AU 2021104419A4 AU 2021104419 A AU2021104419 A AU 2021104419A AU 2021104419 A AU2021104419 A AU 2021104419A AU 2021104419 A4 AU2021104419 A4 AU 2021104419A4
- Authority
- AU
- Australia
- Prior art keywords
- hair
- gel
- formulation
- formulations
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000009472 formulation Methods 0.000 title claims abstract description 73
- 230000012010 growth Effects 0.000 title claims abstract description 7
- 210000003780 hair follicle Anatomy 0.000 title claims description 9
- 230000003779 hair growth Effects 0.000 claims abstract description 23
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 17
- 241000208340 Araliaceae Species 0.000 claims abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 239000002085 irritant Substances 0.000 claims abstract description 9
- 231100000021 irritant Toxicity 0.000 claims abstract description 9
- 210000003491 skin Anatomy 0.000 claims description 20
- 238000011156 evaluation Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000008827 biological function Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 37
- 238000012360 testing method Methods 0.000 abstract description 17
- 206010015150 Erythema Diseases 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 12
- 206010030113 Oedema Diseases 0.000 abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 10
- 231100000321 erythema Toxicity 0.000 abstract description 9
- 239000000284 extract Substances 0.000 abstract description 8
- 230000000977 initiatory effect Effects 0.000 abstract description 5
- 239000000377 silicon dioxide Substances 0.000 abstract description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 4
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 239000000321 herbal drug Substances 0.000 abstract description 3
- 230000037319 collagen production Effects 0.000 abstract description 2
- 230000003646 hair health Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 70
- 201000004384 Alopecia Diseases 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- 208000024963 hair loss Diseases 0.000 description 10
- 230000003676 hair loss Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003349 gelling agent Substances 0.000 description 7
- 241000195950 Equisetum arvense Species 0.000 description 6
- 230000003698 anagen phase Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229960003632 minoxidil Drugs 0.000 description 5
- 206010051814 Eschar Diseases 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 206010068168 androgenetic alopecia Diseases 0.000 description 4
- 201000002996 androgenic alopecia Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 231100000333 eschar Toxicity 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000005768 Equisetum arvense L. Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- -1 lipid peroxides Chemical class 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 206010046742 Urticaria contact Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000003721 exogen phase Effects 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011548 physical evaluation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QNQBPPQLRODXET-AIMHRHHOSA-N (3e,5s)-3-[[(1s,2r,4as,6r,8ar)-1,6-dimethyl-2-[(e)-prop-1-enyl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]-hydroxymethylidene]-5-(hydroxymethyl)-1-methylpyrrolidine-2,4-dione Chemical compound O/C([C@@]1(C)[C@@H]2CC[C@@H](C)C[C@H]2C=C[C@H]1/C=C/C)=C1\C(=O)[C@H](CO)N(C)C1=O QNQBPPQLRODXET-AIMHRHHOSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BVKZYNPBNHCJMO-UHFFFAOYSA-N 3'-deoxyequisetumpyrone Natural products OCC1OC(OC2=C(O)C=C(OC2=O)C=Cc3ccc(O)cc3)C(O)C(O)C1O BVKZYNPBNHCJMO-UHFFFAOYSA-N 0.000 description 1
- ZAQHLKKETXFKKN-UHFFFAOYSA-N 4'-O-methylequisetumpyrone Natural products COc1ccc(C=CC2=CC(=C(OC3OC(CO)C(O)C(O)C3O)C(=O)O2)O)cc1O ZAQHLKKETXFKKN-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- CAQWNKXTMBFBGI-UHFFFAOYSA-N C.[Na] Chemical compound C.[Na] CAQWNKXTMBFBGI-UHFFFAOYSA-N 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YBZUGUWOQLUNKD-PMPSAXMXSA-N Palustrine Chemical compound C1C(=O)NCCCCNCCCN2[C@H]([C@@H](O)CC)CC=C[C@@H]21 YBZUGUWOQLUNKD-PMPSAXMXSA-N 0.000 description 1
- YMALJVLSPODBKM-UHFFFAOYSA-N Palustrine Natural products C1C(=O)NCCCCNCCCN2C(C(O)CC)C=CCC21 YMALJVLSPODBKM-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229930185210 Saponoside Natural products 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007799 dermal corrosion Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- QNQBPPQLRODXET-UHFFFAOYSA-N equisetin Natural products CC=CC1C=CC2CC(C)CCC2C1(C)C(O)=C1C(=O)C(CO)N(C)C1=O QNQBPPQLRODXET-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229960003476 methylparaben sodium Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000001297 telogen effluvium Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
- A61K8/9749—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The traditional system of medicine in India acclaims a number of herbal drugs for hair
growth promotion newline. But herbs can also aid in your hair growth hair goals. Here
we have developed a formulation consisting of horsetail and Ginseng. The silica in
horsetail has been shown to encourage hair growth and hair thickness. Using this extract
also impacts your collagen production in a positive way that will improve your hair
health and overall look.
Dermal irritancy test was conducted to evaluate the irritancy of the prepared gel
formulations on intact skin of rabbits. Gel formulations of EEEA (10 %) and EELN
showed no erythema and no oedema, indicating that the prepared formulations were non
- irritant on the skin of rabbits. Among the various formulations the formulation
containing combination of EEEA (5 %) and EELN (5 %) showed better growth initiation
time and hair growth completion time and also the same formulation showed significant
improvement in hair length compare to control, standard and other gel formulations
containing various concentrations of horsetail and ginseng
Description
Title of Invention
Polyherbal Gel formulation for growth of Hair Follicle.
Background
The hair follicle is a cutaneous organ that remodels itself during cyclical periods of active hair growth (anagen), apoptosis-driven involution (catagen), hair shedding (exogen), and relative rest (telogen) Beside the androgenic hormones, the miniaturization of hair follicle might be explained by a shorter anagen cycle The hair follicle size and the duration of anagen phase indicate the length and the size of hair shaft, respectively The normal duration of anagen is around 2-6 years on average, and then it will turn to a short transitory period of catagen, in which the follicle will undergo apoptosis Therefore, one of the goals for treating androgenetic alopecia is to prolong the anagen
Free radicals, which are highly reactive molecules with unpaired electrons that can directly damage various cellular components, might be another factor affecting the hair loss in androgenetic alopecia. Since the oxidation process leads to progressive damage of cellular structures, the ageing phenotype of hair manifests as a decrease in hair production It has been reported that lipid peroxides on hair follicles led to the early onset of the catagen in murine hair cycles. Therefore, antioxidant compounds might be used to prolong the anagen phase and reduce the hair loss. Nowadays, the potassium channel opener minoxidil and the dihydrotestosterone synthesis inhibitor finasteride have been used for the treatment of androgenetic alopecia However, these chemicals might cause some adverse reactions. Some patients using minoxidil encounter with fast or irregular heartbeat, rapid weight gain, bloating, flushing, redness of skin, swelling of feet or lower legs, etc., whereas, finasteride can cause cold sweats, confusion, dizziness, faintness, loss in sexual ability, etc. Therefore, there is an interest in finding new compounds for the treatment of androgenetic alopecia, especially from natural sources. Deficiency of useful minerals and vitamins in body, Mental and emotional stress, Prolonged illness, Hormonal imbalance is commonly seen in hyperthyroidism, imbalance in androgen, and estrogen, Usually after childbirth due to hormonal imbalance, Certain medications such as blood thinners, vitamin A if taken in excess amount, no contraceptive pills, antidepressant drugs, and medicines used in chemotherapy for treating cancer patients, Certain infections that can promote hair loss, for example, fungal infection on scalp, Diseases such as diabetes may also be a precipitating factor in hair loss, Poor blood circulation or excess blood loss, Poor nutrition, Lack of sleep and lifestyle disorder & Hereditary factors.
Horsetail extract is taken from the horsetail plant, which is technically in the fern family. It's been around since the Paleozoic Era and has been used to stop hemorrhages and treat kidney disease in the past. The name comes from the appearance of the plant, which looks like the mane and tail of a horse. Horsetail (Equisetum arvense) is a plant that has been used as an herbal remedy for centuries.
The botanical name for horsetail is Equisetum arvense. It contains high amounts of silica, which is a compound that strengthens hair and nails. In fact, horsetail is one of the plants that contain the highest amount of silica. Equisetum Linn. is one of the most oldest living genera of vascular plant which comprises about twenty-five species .The most investigated species was Equisetum arvense L. which has been widely used in traditional medicines for the treatment of hair loss . Historically, it was used as a diuretic to increase the frequency of urination. In recent years, it has developed a reputation as a hair care and hair loss remedy.
The mixture of E. arvense shoot extract and ginseng has been used as a hair tonic Additionally, the superior reduction of telogen effluvium duration in patients treated with herbal drug containing E. arvense extract (seven weeks) comparing to minoxidil solution (seven weeks) has also been reported.
Horsetail extract is known to improve the circulation of your blood, which in turn leads to healthy hair follicles. It has antioxidant properties that also work as a detox for your hair and body. When your scalp gets enough blood, it increases its ability to produce more hair.
The silica in horsetail has been shown to encourage hair growth and hair thickness. Using this extract also impacts your collagen production in a positive way that will improve your hair health and overall look.
Since it has been shown to help with hair growth and stimulating the follicles, horsetail has been used in cases of hair loss. There isn't a large amount of scientific evidence to back this up, but many people swear by its effects in the way that silica interacts with keratin and improves its structure, making hair stronger.
E. arvense L. contains various chemical compounds such as silicic acid, linoleic acid, oleic acid, stearic acid, linolenic acid and traces of alkaloids (e.g., equisetin, nicotine, palustrine, and palustrinine), glucoside, flavonoids, saponosides, triterpenoids, phytosterols, calcium carbonate, potassium sulfate, potassium chloride, manganese chloride, iron, manganese, and calcium phosphate Indeed, Veit et al. isolated two styrylpyrone glucosides (3'-deoxyequisetumpyrone and 4'-O-methylequisetumpyrone) from the MeOH extract from the rhizomes ofE. arvense.
Ginseng has been shown to promote hair growth in several recent studies. However, its effects on human hair follicles and its mechanisms of action have not been sufficiently elucidated. Red ginseng extract and its ginsenosides may enhance hDPC proliferation, activate ERK and AKT signaling pathways in hDPCs, upregulate hair matrix keratinocyte proliferation, and inhibit the DHT-induced androgen receptor transcription. These results suggest that red ginseng may promote hair growth in humans.
Description of Invention
Method of Preparation
Preparation of base hair gel
• Measured quantity of methyl paraben, glycerin and weighed quantity of polyethylene glycol were dissolved in 35 ml of water in a beaker. Then it was stirred at high-speed using mechanical stirrer.
• Then Carbopol 934 or sodium CMC and PVP were added slowly to the beaker containing above liquid while stirring.
• Then triethanolamine (gelling agents) was added slowly while stirring to attain gel structure.
• The gel was finally transferred to aluminum collapsible tubes and labelled accordingly. Different composition in base gel formulation is mentioned in Table 1.
Evaluation of base hair gel Formulation Physical appearance
The physical appearance was visually checked for the colour, appearance and the feel on application of prepared hair gel formulation was noted.
pH determination
The pH of all hair gel formulations were determined by using the digital pH meter. One gram of gel was dissolved in 100 ml distilled water and stored for two hours. Electrodes were completely dipped into the hair gel formulations and pH was noted. The measurement of pH of each formulation was done in triplicate and average values were calculated.
Extrudability determination
The hair gel formulations were filled into collapsible metal tubes. The tubes were pressed to extrude the material and the extrudability of the formulations was checked. The extrudability of the formulation was determined in terms of weight in grams required to extrude a 0.5 cm ribbon of gel in 10 seconds.
Viscosity determination
The viscosity of the prepared gel formulations was measured by Brook field viscometer model LV - DV-II +. The sufficient quantity of gel was filled in wide mouth jar separately. The height of the gel filled in the wide mouth jar should sufficiently allow dipping the spindle. The RPM of the spindle was adjusted to 2.5 RPM. The viscosities of the formulations were recorded.
Spreadability
It indicates the extent of area to which gel readily spreads on application to skin or affected part. The therapeutic potency ofa formulation also depends upon its spreading value. Spreadability is expressed in terms of time in seconds taken by two slides to slip off from gel which is placed in between the slides under the direction of certain load.
Lesser the time taken for the separation of two slides, better the spreadability. It is calculated by using the formula
S = M. L / T where,
M= Weight tied to upper slide L= Length of glass slide T= Time taken to separate the slides
Stability studies
The stability studies were carried out for all the prepared gel formulations by freeze - thaw cycling. Here, by subjecting the formulations to a temperature of 40 C for one month, then at 250 C for one month and then 400 C for one month and syneresis was observed. After this, the gel is exposed to ambient room temperature and liquid exudate separating is noted.
Homogeneity
After the gel formulations have been set in the container, all developed gels were tested for homogeneity by visual inspection. They were tested for their appearance and presence of any lumps, flocculates or aggregates.
Grittiness
All prepared gel formulations were evaluated microscopically for the presence of any appreciable particulate matter which was seen under light microscope. Hence obviously the gel preparation fulfils the requirement of freedom from particular matter and from grittiness as desired for any topical preparation (Kaur et al., 2010).
Results
Optimization and selection of gel formulation
One of the main ingredients of the gel formulation is the gelling agent. The concentration of viscosity enhancer or gel former is of immense value as a less concentration will lead to simple solution or lotion with very low consistency, while high
concentration may lead to formation of gels with high viscosity leading to non - uniform distribution of drug and problem with handling of gel formulation. Two different gel formers with various concentrations were tried in order to select the best gelling agent. Gels containing sodium CMC showed phase separation and are poor in consistency as indicated by spreadability and extrudability values, hence these gel formulations were rejected. Gels containing 0.5 % and 1 % of Carbopol 934 form a very thin gel that liquefies within 4 and 5 hours of preparation respectively. With 1.5 % Carbopol 934 gelling agent to some extent better gel was obtained but the problem of liquefaction after 28 hours was observed. Gel formulation containing 2 % of Carbopol 934 formed uniform and smooth gel that does not liquefy upon keeping long time.
The pH of the formulation was determined in order to be sure that the formulation can be used without the risk of irritancy to the skin. The pH was found to be 7.56 for G4 gel formulation which was very nearer to the neutral skin pH, thus the formulation G4 can be used without the risk of irritancy to the skin. This also indicated that the selected ingredients of the formulation did not alter the pH of the formulation
The spreadability of formulations was found to decrease with increasing the concentration of gelling agent. The value of spreadability for optimized gel was found to be 10.2 cm indicating that the gel is easily spreadable by small amount of shear. The results indicated that the formulation can be applied easily without being runoff. This promises that the formulation maintain a good wet contact time when applied to the site of application. According to the present study, 2 % of Carbopol 934 was selected as the optimized concentration of gelling agent and this gel formulation is used for further herbal hair gel preparations.
Preparation of herbal hair gel formulation
Herbal hair gel formulation was prepared with Ethyl acetate extract in ethanol 5
% (HG1) and 10 % (HG2), 5 % (HG3), 10 % (HG4) and combination of these HG1 & HG2 (5 %) and (5 %) (HG5) and pharmaceutical parameters were evaluated. Measured quantity of methyl paraben, glycerin and weighed quantity of polyethylene glycol were dissolved in about 35 ml of water in beaker. Then it was stirred at high-speed using mechanical stirrer. Then carbopol 934 and PVP were added slowly to the beaker containing above liquid while stirring. Crushed menthol was incorporated slowly in above dispersion after smooth dispersion is obtained. Then triethanolamine (gelling agents) was added slowly while stirring to attain gel structure. The ethyl acetate soluble fraction of ethanolic extract of horse tail and Ginseng was levigated using stainless steel spatula and porcelain slab.
Different composition in preparing herbal hair gel is mentioned in Table 2
Evaluation of herbal hair gel formulations
The physical appearance was visually checked for the colour, appearance and the feel on application of prepared herbal hair gel formulation were noted. And also other evaluation parameters like pH, viscosity, extrudability, spreadability, homogeneity and grittiness, feel of application, stability and consistency were evaluated as per the methods mentioned earlier in evaluation for base gel formulations. The results for the evaluation parameters of herbal hair gel are tabulated in Table 2.
From the physical evaluation the color of prepared herbal hair gels was pale green in color and appearance of gel was translucent and it was smooth on application. So it shows significant physical evaluation parameters. The subjective properties such as consistency were good and texture of prepared herbal hair gel was found to be smooth. The pH value of the prepared gel formulation was observed at room temperature and valued range at 7.2 to 7.6. As we go from epidermis to dermis, pH of the skin increases and attained the neutral value. So gel formulation having pH range 7.2 to 7.6 are desirable to skin since they do not interfere with the physiology ofskin.
The prepared herbal gel formulation were subjected to accelerated stability testing. The prepared herbal gel was stored at 40 C, 250 C and 450 C in refrigeration, room temperature and oven for a period of 30 days to study effect of temperature and at different humidity condition. The physical parameters were evaluated during study period. The result of the study indicates that the preparation is physically stable at all temperatures tested.
Evaluation of EEEA and EELN gel formulation against dermal irritancy (OECD Guideline 404)
Skin irritation
The substances that induce inflammation are known as irritants. Inflammation may be caused by use either immediately or through prolonged use or on repeated use. Irritants may be classified as primary irritants and secondary irritants. Primary irritants cause inflammation on the first contact (the duration of contact may be of several hours). Secondary irritants are harmless on first contact but cause inflammation on repeated contact and inflammation becomes more severe with progressive contacts. Contact urticaria means local oedema (swelling) and erythema (increased blood flow) at the site of application of a substance. Contact urticaria may be allergic or nonallergic. Some substances cause ill defined response when applied to the skin. This response is generally termed as stinging. The other terms which refer to this response are itch, tingle, burn or sore. This response starts within minutes of application of substance, intensifies within next 5 - 10 minutes and then vanishes. This phenomenon is different from irritation and does not lead to inflammatory change.
Test Procedure Application of the test substance Half a gram of the herbal gel formulation was applied to a small area (approximately 6 cm 2 ) of skin and covered with a gauze patch, which is held in place with non-irritating tape. In cases in which direct application is not possible (e.g., liquids or some pastes), the test substance was first be applied to the gauze patch, which is then applied to the skin. The patch was loosely held in contact with the skin by means of a suitable semi - occlusive dressing for 4 hours duration of the exposure period and then removed. If the test substance is applied to the patch, it was attached to the skin in such a manner that there is good contact and uniform distribution of the substance on the skin. Access by the animal to the patch and ingestion or inhalation of the test substance was prevented. At the end of the exposure period, which was normally 4 hours, residual test substance was removed using water or an appropriate solvent without altering the existing response or the integrity of the epidermis.
Initial test (In vivo dermal irritation/corrosion test using one animal) It was strongly recommended that the in vivo test be performed initially using one animal, especially when the substance was suspected to have corrosion potential. This was in accordance with the sequential testing strategy. When a substance has been judged to be corrosive on the basis of a weight-of theevidence analysis, no further animal testing is needed. For most substances suspected of being corrosive, further in vivo testing is normally not necessary. However, in those cases where additional data are felt warranted because of insufficient evidence, limited animal testing may be carried out using the following approach: Up to three test patches were applied sequentially to the animal. The first patch was removed after three minutes. If no serious skin reaction was observed, a second patch was applied at a different site and removed after one hour. If the observations at this stage indicate that exposure can humanely be allowed to extend to four hours, a third patch was applied and removed after four hours, and the response was graded. If a corrosive effect was observed after any of the three sequential exposures, the test was immediately terminated. If a corrosive effect was not observed after the last patch was removed, the animal was observed for 14 days, unless corrosion develops at an earlier time point. In those cases in which the test substance was not expected to produce corrosion but may be irritating, a single patch was applied to one animal for four hours.
Grading of skin reactions - Erythema and Eschar Formation
N o ery them a ........................................................................................................... 0
Very slight erythema (barely perceptible) .............................................................. 1
W ell defined erythem a ..... ............................................................................. . 2
M oderate to severe erythem a .......................................................................... . 3
Severe erythema to eschar formation preventing grading of erythema............... 4
Maximum possible: 4
Oedema Formation
N o o ed em a ..................................................... ......................................................... 0
V ery slight oedem a (barely perceptible) ................................................................... 1
Slight oedema (edges of area well defined by definite raising) ........................... 2
Moderate oedema (raised approximately 1 mm) .................................................. 3
Severe oedema (raised more than 1 mm and extending beyond area of exposure)... 4
Maximum possible: 4
Both the control and the test animals were observed every day for any occurrence of skin irritation or toxic reactions such as oedema or erythema. Per observation of skin,
A value between 0 and 4 was recorded where 0 meant no skin erythema and eschar formation and 1, 2, 3 and 4 stood for very slight, well defined, moderate and severe erythema to eschar formation, respectively. It also scored from 0 - 4, where 0 stood for no oedema and 4 stood for severe oedema
Evaluation of EEEA and EELN for hair growth promoting activity
Qualitative hair growth study Qualitative hair growth analysis was undertaken by visual
observation of two parameters: hair growth initiation time (i.e. minimum time to initiate hair
growth on denuded skin region) and hair growth completion time (i.e. minimum time taken to complete cover the denuded skin region with new hair)
Table 1 : Different composition of base gel formulation
Methyl Sodium Carbopol PVP paraben Glycerine PEG Triethanol Formulation CMC 934 (g) (mg) sodium (ml) (ml) amine
(g) (mg) (ml)
GI - 0.5 5 75 3 6.25 0.6
G2 - 1.0 5 75 3 6.25 0.9
G3 - 1.5 5 75 3 6.25 1.2
G4 - 2.0 5 75 3 6.25 1.5
G5 0.5 - 5 75 3 6.25 0.6
G6 1.0 - 5 75 3 6.25 0.9
G7 1.5 - 5 75 3 6.25 1.2
G8 2.0 - 5 75 3 6.25 1.5
Table 2. Formulae of herbal hair gel
Formulation HG1 HG2 HG3 HG4 HG5
5%of 10%of 5%of 10%of 5%ofEEEA+ Herbal Extract (g) EEEA EEEA EELN EELN 5 % of EELN
Carbopol934(g) 2 2 2 2 2
PVP (mg) 5 5 5 5 5
Methyl paraben sodium (mg) 75 75 75 75 75
Glycerine (ml) 3 3 3 3 3
PEG (ml) 6.25 6.25 6.25 6.25 6.25
Triethanolamine (ml) 1.5 1.5 1.5 1.5 1.5
Table 3. Evaluation of base hair gel formulation
Formulations
Parameters Gi G2 G3 G4 G5 G6 G7 G8
Feel of Smooth Smooth Smooth Smooth Smooth Smooth Smooth Smooth application
Spreadability 12.7 10.9 10.2 6.3 5.5 4.8 4.2 (g.cm/sec) 13.5
Excellent Consistency Poor Good Good uniform Poor Poor Fairly Good
gel good
pH 6.69 6.91 7.12 7.56 6.91 7.02 7.35 7.41
Viscosity 85,065 1,00,080 1,52,013 50,075 62,000 81,072 92,070 (cps) 82,000
Extrudability Good Good Excellent Excellent Poor Poor Good Good
Table 4. Evaluation parameters of herbal hair gel formulation
Formulations
Parameters HGI HG2 HG3 HG4 HG5
Colour Pale green Pale green Pale green Pale green Pale green colour colour colour colour colour
Appearance Translucent Translucent Translucent Translucent Translucent
Odour Pleasant Pleasant Pleasant Pleasant Pleasant odour odour odour odour odour
Spreadability 10.7 10.6 10.2 10.7 10.9 (g cm/sec)
Homogeneity Good Good Good Good Good
Feel of Smooth Smooth Smooth Smooth Smooth application
Consistency Good Good Good Good Good
pH 7.6 7.2 7.5 7.4 7.2
Viscosity 1,52,000 1,51,065 1,52,070 1,52,013 1,52,075 (cps)
Extrudability Excellent Excellent Excellent Excellent Excellent
Stability Stable Stable Stable Stable Stable
Table 5
Effect of EEEA and EELN gel formulation on hair growth initiation and completion time
Hair growth in days Per cent
Treatments reduction in hair Initiation time Completion time growth completion time*
Negative control - simple gel 11.8 0.94 42.6 1.50
Positive control - 2 % minoxidil 6.07 0.42 33.0 0.71 23.55***
5 % EEEA (HG1) 10.4 0.86 35.0 0.41 15.51
10 % EEEA (HG2) 8.01 0.64 33.4 0.49 23.96***
5 % EELN (HG3) 11.3 0.57 40.2 0.99 7.69.
10 % EELN (HG4) 13.4 0.61 36.2 0.58 18.39
5 % EEEA + 5 % EELN (HG5) 6.03 0.81 28.2 0.76 34.75*** * (Mean of control - Mean of treatment) / Mean of control X 100 ***P < 0.05 significant when compared to control (ANOVA followed by Dunnett's test; Values are mean ±SEM
Summary
Hair loss is a dermatological disorder, and the surge for discovering natural products with hair growth promoting potential is continuous. Hair loss or alopecia is a common patient complaint and a source of significant psychological and physical distress. Androgens are considered to be one of the most important causes for alopecia apart from a variety of other factors. Minoxidil, a drug of scientific origin was scientifically proved for the treatment of alopecia. Though the side effect associated with this drug has limited its pharmacological benefits hence the drug of plant origin is necessary to replace the synthetic one. Thus it is very important to develop new therapeutic materials to stop hair loss and to enhance hair growth. Alternative medicine is one interesting area, which is getting more popular. Although it has not yet been incorporated into the mainstream of medical care because of limited scientific evidences and lack of mechanistic understanding, alternative medicine is becoming an increasingly attractive approach all over the world. Natural products in the form of herbal formulations are available on the market and are used as hair tonic, hair growth promoter, hair conditioner, hair-cleansing agent, antidandruff agents, as well as for the treatment of alopecia and lice infection. A number of herbal products have been acclaimed with hair growth promoting activity. The traditional system of medicine in India acclaims a number of herbal drugs for hair growth promotion but lack of sound scientific backing and information limits their use. The determination of physicochemical constants such as moisture content, ash values, extractive values and elemental composition of aerial parts of Horsetail and Ginseng were carried out to confirm the identity of herb and to ascertain the quality and purity of the drug. These physical parameters are useful in establishing quality profile of drug and constitute an important component of qualitative evaluation. Plants with possible antimicrobial activity should be tested against an appropriate microbial model to confirm the activity and to ascertain the parameters associated with it.
Horsetail and Ginseng are important plants among many traditional herbs in the treatment of
many diseases, which are usually free from side effects, are economical and also easily accessible to humans. On the basis of our results of the present study, it is concluded that the ethyl acetate fraction of ethanolic extract of Horsetail and Ginseng and the isolated compounds EA - 1 and LN - 1 have significant antibacterial and antifungal activity. So these two plants can be considered for preparation of nutraceuticals with potent antimicrobial activity suitable for the prevention of human disease. Therefore these extracts can be considered as a potential source of natural antioxidant agent. gel formulations were prepared with EEEA 5 %, EEEA 10 %, EELN 5 % and EELN 10 % and physical parameters were evaluated. Hence this herbal gel formulation was utilized for further pharmacological studies. Dermal irritancy test was conducted to evaluate the irritancy of the prepared gel formulations on intact skin of rabbits. Gel formulations of EEEA (10 %) and EELN showed no erythema and no oedema, indicating that the prepared formulations were non - irritant on the skin of rabbits. Among the various formulations the formulation containing combination of EEEA (5 %) and EELN (5 %) showed better growth initiation time and hair growth completion time and also the same formulation showed significant improvement in hair length compare to control, standard and other gel formulations containing various concentrations of horsetail and ginseng.
Claims (5)
1) Herein we claim a Polyherbal Gel formulation for growth of Hair Follicle, which helps in hair growth.
2) The gel formulation developed in1 is developed with various concentrations of horsetail and ginseng.
3) The gel formulation developed in 1 is non - irritant on the skin.
4) The gel formulation developed in 1 is applied topically as cosmetics but contain ingredients that influence the skins biological function.
5) We also claim the method of preparation and evaluation of formulation claimed in 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021104419A AU2021104419A4 (en) | 2021-07-22 | 2021-07-22 | Polyherbal Gel formulation for growth of Hair Follicle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021104419A AU2021104419A4 (en) | 2021-07-22 | 2021-07-22 | Polyherbal Gel formulation for growth of Hair Follicle |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021104419A4 true AU2021104419A4 (en) | 2022-05-19 |
Family
ID=81588675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021104419A Ceased AU2021104419A4 (en) | 2021-07-22 | 2021-07-22 | Polyherbal Gel formulation for growth of Hair Follicle |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021104419A4 (en) |
-
2021
- 2021-07-22 AU AU2021104419A patent/AU2021104419A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410062B1 (en) | Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) | |
US7387807B2 (en) | Topical composition comprising feverfew | |
US6333057B1 (en) | Composition and method for topical treatment of androgenic alopecia | |
TWI669116B (en) | Compositions and methods for treating hair loss and delaying aging of skin | |
JP2009532342A (en) | NOVEL COMPOSITION FOR HAIRHAIR DISEASE AND METHOD FOR PREPARING THE SAME | |
JP2009137984A (en) | Topical composition containing natural component and method of its use | |
JPS6330884B2 (en) | ||
JP2609564B2 (en) | Cream for allergic dermatitis and method for producing the same | |
AU2021104419A4 (en) | Polyherbal Gel formulation for growth of Hair Follicle | |
Kamkaen et al. | The investigation of the rabbit and human skin irritation of herbal anti-wrinkle cream | |
US8334001B2 (en) | Composition comprising mucilaginous polysaccharides derived from aloe barbadensis and method for obtaining same and use thereof | |
RU2122396C1 (en) | Bioactive addition to cosmetics | |
Ugoeze et al. | Evaluation of the wound healing potentials of aqueous topical creams containing aqueous extract of Azadirachta indica leaves as bioactive ingredient | |
RU2286140C1 (en) | Cream for sensitive skin | |
EP1875908A1 (en) | Use of Chrysin | |
JPH0112725B2 (en) | ||
AU2021103389A4 (en) | A Skincare Serum | |
US6187815B1 (en) | Methods and compositions for the promotion of hair growth | |
RU2448683C1 (en) | Milk-wax walnut and buckeye ointment | |
US20220339234A1 (en) | Natural-substance composition for the topical treatment and care of psoriatic skin and other skin diseases | |
KR20070005297A (en) | Composition for reduction of sebum and alleviating acne | |
PAVLOVIĆ et al. | IN VITRO MULLEIN OIL INVESTIGATIONS AND IN VIVO EFFECTS OF MULLEIN OIL CREAM ON HUMAN SKIN PHYSIOLOGY | |
Divya | A Comparative Pharmaceutico-Analytical and Clinical Evaluation of Vatapatradi Lepa with and Without Varuna Twak Kashaya Prakshalana on Yauvana Pidaka (Acne Vulgaris) | |
TWI344369B (en) | Topical compositions having a natural ingredient and method of use | |
KR20040065864A (en) | Prevention and alleviation composition of skin allergy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |